Acurx Pharmaceuticals (ACXP) Total Non-Current Liabilities (2021 - 2022)
Acurx Pharmaceuticals' (ACXP) quarterly Total Non-Current Liabilities came in at -$144121.0 in Q2 2022, down 1059.02% quarter-over-quarter from $15028.0 in Q1 2022.
Powered by 
Analysis
Acurx Pharmaceuticals (ACXP) Total Non-Current Liabilities (2021 - 2022) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has reported Total Non-Current Liabilities for 2 consecutive years, with -$144121.0 the latest figure, recorded in Q2 2022.
- For the quarter ending Q2 2022, Total Non-Current Liabilities changed N/A year-over-year to -$144121.0; the trailing twelve-month figure through Jun 2022 stood at -$144121.0 (changed N/A YoY), and the FY2021 full-year result was $225909.0, changed N/A from the prior year.
- Total Non-Current Liabilities eased to -$144121.0 in Q2 2022 per ACXP's latest filing, from $15028.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $225909.0 in Q4 2021 and bottomed at -$144121.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | 1.53 Bn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Acurx Pharmaceuticals | 6.65 Mn | 6.65 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | -144,121.00 |
| Mar 31, 2022 | 15,028.00 |
| Dec 31, 2021 | 225,909.00 |